Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Saad Z. Usmani"'
Publikováno v:
American Journal of Hematology
Daratumumab is a human CD38-directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI) and an immunomod
Autor:
Antje Hoering, Saad Z. Usmani
Publikováno v:
Leukemia. 27:2269-2271
Since the year 2000, there has been a continued improvement in survival outcomes for multiple myeloma (MM) patients,1 attributable to the clinical development and inclusion of novel agents in upfront therapy, and improvement in high-dose therapy admi
Autor:
Sagar Lonial, Saad Z. Usmani
Publikováno v:
Clinical lymphoma, myelomaleukemia.
The outcomes and management of multiple myeloma (MM) in the United States have changed dramatically over the past 15 years with the approval by the US Food and Drug Administration (FDA) of 6 new drugs (thalidomide, lenalidomide, bortezomib, pegylated
Autor:
Mahrukh K. Ganapathi, Ram N. Ganapathi, B Tunquist, Saad Z. Usmani, Eric J. Norris, Darla Destephanis
Publikováno v:
Blood Cancer Journal
Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells
Autor:
Parameswaran Hari, Jeffrey A. Zonder, Saad Z. Usmani, Noopur Raje, Larry D. Anderson, Jennifer Schreiber, Jason Valent, Emma C. Scott, Roger Aitchison, Seema Singhal, Michael Craig, Mieke Ptaszynski, Jesus G. Berdeja, Gregory Orloff, Craig C. Hofmeister, Nikoletta Lendvai
Publikováno v:
Web of Science
TPS8612 Background: Immunomodulatory agent (IMiD)/bortezomib (BTZ) combinations are common frontline therapy in patients with multiple myeloma (MM). Despite high initial objective response rates (O...
Autor:
Susan Panozzo, Saad Z. Usmani, A Tullos, Shebli Atrash, F. van Rhee, Bart Barlogie, Manisha Bhutani
Publikováno v:
Blood Cancer Journal
Carfilzomib is a novel, highly selective, tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, which is the proteolytic core particle within the 26S proteasom
Autor:
Saad Z. Usmani, Ya-Wei Qiang, Christoph Heuck, Frits van Rhee, Bart Barlogie, Joshua Epstein, Sarah Waheed, Susan Panozzo, Clyde Bailey, Qing Zhang
Publikováno v:
Blood. 120:5015-5015
Abstract 5015 BACKGROUND: The introduction of bortezomib (BOZ) – the first FDA-approved proteasome inhibitor (PI) – as a therapeutic option for multiple myeloma (MM) has significantly improved patient outcomes in the last decade. However, relapsi
Autor:
Jackie Szymonifka, Saad Z. Usmani, Yazan Alsayed, Bart Barlogie, Susan Panozzo, Bijay Nair, John Crowley, Sarah Waheed, Rachael Sexton
Publikováno v:
Journal of Clinical Oncology. 29:8028-8028
8028 Background: CFZ is an epoxomicin derivative with ability to irreversibly inhibit proteosomes, with clinical activity. It has been shown in preclinical and early clinical studies to have activi...